Lead Product(s) : FCX-013,Veledimex
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The open label, single cohort Phase 1/2 clinical trial is evaluating the safety of FCX-013 as its primary objective. Secondary objectives include assessments of fibrosis at targeted sclerotic lesions at various time points through 26 weeks post-administr...
Product Name : FCX-013
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 15, 2020
Lead Product(s) : FCX-013,Veledimex
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable